• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors.

作者信息

Coleman Emily, Panse Gauri, Cowper Shawn, Lacy Jill, Leventhal Jonathan

机构信息

Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.

Department of Pathology, Yale University School of Medicine, New Haven, Connecticut.

出版信息

JAAD Case Rep. 2019 Jan 30;5(2):170-172. doi: 10.1016/j.jdcr.2018.11.021. eCollection 2019 Feb.

DOI:10.1016/j.jdcr.2018.11.021
PMID:30740499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6357547/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d5/6357547/08881b1c38cc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d5/6357547/09daf4cf0cdb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d5/6357547/08881b1c38cc/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d5/6357547/09daf4cf0cdb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0d5/6357547/08881b1c38cc/gr2.jpg

相似文献

1
Disappearing pigmentary mosaicism during imatinib treatment for gastrointestinal stromal tumors.伊马替尼治疗胃肠道间质瘤期间色素脱失性镶嵌现象消失。
JAAD Case Rep. 2019 Jan 30;5(2):170-172. doi: 10.1016/j.jdcr.2018.11.021. eCollection 2019 Feb.
2
RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.RACK1过表达与胃肠道间质瘤中获得性伊马替尼耐药相关。
Oncotarget. 2016 Mar 22;7(12):14300-9. doi: 10.18632/oncotarget.7426.
3
Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.靶向 WEE1 激酶通过促进胃肠道间质肿瘤中 KIT 的自噬降解增强伊马替尼的抗肿瘤活性。
Gastric Cancer. 2020 Jan;23(1):39-51. doi: 10.1007/s10120-019-00977-1. Epub 2019 Jun 13.
4
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.KIT和ABL1在胃肠道间质瘤（GIST）细胞对甲磺酸伊马替尼治疗反应中的相反作用。
Oncotarget. 2017 Jan 17;8(3):4471-4483. doi: 10.18632/oncotarget.13882.
5
Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors.胰岛素受体和 KIT 的双重靶向治疗伊马替尼耐药胃肠间质瘤。
Cancer Res. 2017 Sep 15;77(18):5107-5117. doi: 10.1158/0008-5472.CAN-17-0917. Epub 2017 Jul 31.
6
CCDC26 knockdown enhances resistance of gastrointestinal stromal tumor cells to imatinib by interacting with c-KIT.CCDC26基因敲低通过与c-KIT相互作用增强胃肠道间质瘤细胞对伊马替尼的耐药性。
Am J Transl Res. 2018 Jan 15;10(1):274-282. eCollection 2018.
7
KIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumors.p55PIK-PI3K导致的KIT过表达会使胃肠道间质瘤患者产生伊马替尼耐药性。
Oncotarget. 2016 Jan 12;7(2):1367-79. doi: 10.18632/oncotarget.6011.
8
Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.胃肠道间质瘤中伊马替尼耐药与 KIT 和 PDGFRA 基因突变状态的相关性：一项荟萃分析。
J Gastrointestin Liver Dis. 2013 Dec;22(4):413-8.
9
Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors.KIT的药理学抑制激活胃肠道间质瘤中的MET信号通路。
Cancer Res. 2015 May 15;75(10):2061-70. doi: 10.1158/0008-5472.CAN-14-2564. Epub 2015 Apr 2.
10
Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.甲磺酸伊马替尼：用于治疗胃肠道间质瘤。
Drugs. 2003;63(5):513-22; discussion 523-4. doi: 10.2165/00003495-200363050-00005.

引用本文的文献

1
Familial gastrointestinal stromal tumors with germline mutation in a Chinese family: A case report.一个中国家族中具有胚系突变的家族性胃肠道间质瘤：病例报告
World J Clin Cases. 2022 May 26;10(15):4878-4885. doi: 10.12998/wjcc.v10.i15.4878.

本文引用的文献

1
Cutaneous Adverse Events of Targeted Therapies for Hematolymphoid Malignancies.血液淋巴系统恶性肿瘤靶向治疗的皮肤不良事件
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):834-851. doi: 10.1016/j.clml.2017.07.005. Epub 2017 Jul 14.
2
Mosaicism for a KITLG Mutation in Linear and Whorled Nevoid Hypermelanosis.线状和涡状痣样黑素沉着症中KITLG基因突变的嵌合现象
J Invest Dermatol. 2017 Jul;137(7):1575-1578. doi: 10.1016/j.jid.2017.01.035. Epub 2017 Feb 28.
3
Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome.
接受伊马替尼治疗的家族性胃肠道间质瘤综合征患者的雀斑样痣消失。
Arch Dermatol. 2009 Nov;145(11):1313-6. doi: 10.1001/archdermatol.2009.263.
4
Imatinib mesilate inhibits melanogenesis in vitro.甲磺酸伊马替尼在体外抑制黑色素生成。
Br J Dermatol. 2006 Aug;155(2):493-4. doi: 10.1111/j.1365-2133.2006.07359.x.
5
c-kit Mutation in generalized lentigines associated with gastrointestinal stromal tumor.与胃肠道间质瘤相关的泛发性雀斑样痣中的c-kit突变
Dermatology. 2004;208(3):217-20. doi: 10.1159/000077302.
6
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.接受甲磺酸伊马替尼治疗的慢性髓性白血病患者的色素沉着变化。
Ann Oncol. 2004 Feb;15(2):358-9. doi: 10.1093/annonc/mdh068.
7
Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo.c-kit受体在色素减退症中的表达：斑驳病、色素脱失痣与白癜风的比较研究
Br J Dermatol. 1995 Feb;132(2):182-9. doi: 10.1111/j.1365-2133.1995.tb05011.x.